| Q33911349 | Ambiguous melanocytic tumors with loss of 3p21. |
| Q24599005 | An emerging model for BAP1's role in regulating cell cycle progression |
| Q24329078 | Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1 |
| Q85236158 | BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations |
| Q47428787 | BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer |
| Q37221089 | BAP1 and cancer |
| Q104577032 | BAP1 binds BRCA1:BARD1 heterodimer |
| Q61124903 | BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation |
| Q37355644 | BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma |
| Q104577037 | BAP1 disrupts the BRCA1:BARD1 heterodimer |
| Q54669259 | BAP1 germline mutation in two first grade family members with uveal melanoma. |
| Q52568577 | BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. |
| Q96430967 | BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice |
| Q24339530 | BAP1 is phosphorylated at serine 592 in S-phase following DNA damage |
| Q34280223 | BAP1 loss defines a new class of renal cell carcinoma |
| Q35591969 | BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line |
| Q35792362 | BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. |
| Q90294125 | BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers |
| Q38545726 | BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies |
| Q33890512 | BAP1, a tumor suppressor gene driving malignant mesothelioma |
| Q37507563 | BRCA1 and its toolbox for the maintenance of genome integrity |
| Q90223367 | BRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma |
| Q34353359 | Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma |
| Q39515506 | Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. |
| Q43806776 | Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. |
| Q48326636 | Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. |
| Q94474304 | DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer |
| Q38336126 | DUBs, the regulation of cell identity and disease |
| Q36502572 | Deubiquitinating enzyme BAP1 is involved in the formation and maintenance of the diapause embryos of Artemia |
| Q38843978 | Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis |
| Q92421826 | Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma |
| Q90575977 | Dissenting degradation: Deubiquitinases in cell cycle and cancer |
| Q27664221 | Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase |
| Q41574276 | Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma |
| Q24338634 | Erythroid differentiation-associated gene interacts with NPM1 (nucleophosmin/B23) and increases its protein stability, resisting cell apoptosis |
| Q47248762 | Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. |
| Q26781153 | Fine-tuning the ubiquitin code at DNA double-strand breaks: deubiquitinating enzymes at work |
| Q39399033 | Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma |
| Q24601069 | Frequent mutation of BAP1 in metastasizing uveal melanomas |
| Q38870857 | Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells |
| Q41084421 | Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma |
| Q27671821 | Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains |
| Q58612052 | Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer |
| Q33698718 | Melanoma epidemiology, biology and prognosis |
| Q38146707 | Melanoma mutagenesis and aberrant cell signaling |
| Q33649025 | Molecular markers of paragangliomas/pheochromocytomas |
| Q90028615 | NUMB enhances Notch signaling by repressing ubiquitination of NOTCH intracellular domain |
| Q26770424 | New concepts on BARD1: Regulator of BRCA pathways and beyond |
| Q36205186 | New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment |
| Q36589947 | Ovarian cancer: in search of better marker systems based on DNA repair defects |
| Q38122565 | PBRM1 and BAP1 as novel targets for renal cell carcinoma |
| Q38646960 | Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma |
| Q40070779 | Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. |
| Q98647386 | Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: evidence for further locus heterogeneity |
| Q37975137 | Pathological and molecular biological approaches to early mesothelioma |
| Q49698247 | Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma |
| Q38397568 | Prognostic significance of BRCA1-associated protein 1 in colorectal cancer |
| Q38120938 | Regulation of proteolysis by human deubiquitinating enzymes |
| Q49829001 | Role of BRCA Mutations in the Modulation of Response to Platinum Therapy |
| Q57755309 | Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis |
| Q61812961 | Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment |
| Q38959150 | Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity |
| Q34496129 | The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer |
| Q37875478 | The BRCA1 ubiquitin ligase and homologous recombination repair |
| Q38214084 | The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment |
| Q90157623 | The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis |
| Q37742632 | The biology of uveal melanoma |
| Q24323060 | The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. |
| Q39021700 | The epigenetic landscape of renal cancer |
| Q34769556 | The relative timing of mutations in a breast cancer genome |
| Q34564968 | The role of deubiquitinating enzymes in chromatin regulation. |
| Q28083152 | The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer |
| Q24633127 | The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression |
| Q37474898 | Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair |
| Q47592158 | Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications |
| Q47155655 | Ubiquitin recognition of BAP1: understanding its enzymatic function |
| Q47119023 | miR-31 Functions as an Oncomir Which Promotes Epithelial-Mesenchymal Transition via Regulating BAP1 in Cervical Cancer. |